Sartorius (SRT3) Given a €162.00 Price Target by Warburg Research Analysts

Sartorius (FRA:SRT3) has been assigned a €162.00 ($188.37) price target by investment analysts at Warburg Research in a research report issued on Wednesday, Borsen Zeitung reports. The firm presently has a “neutral” rating on the stock. Warburg Research’s price objective suggests a potential upside of 0.81% from the company’s current price.

A number of other analysts have also recently weighed in on the stock. Nord/LB set a €115.00 ($133.72) target price on shares of Sartorius and gave the stock a “sell” rating in a report on Tuesday. Kepler Capital Markets set a €107.00 ($124.42) target price on shares of Sartorius and gave the stock a “sell” rating in a report on Thursday, April 18th. UBS Group set a €147.00 ($170.93) target price on shares of Sartorius and gave the stock a “neutral” rating in a report on Thursday, April 18th. Deutsche Bank set a €150.00 ($174.42) target price on shares of Sartorius and gave the stock a “neutral” rating in a report on Thursday, April 11th. Finally, Hauck & Aufhaeuser set a €130.00 ($151.16) target price on shares of Sartorius and gave the stock a “sell” rating in a report on Thursday, April 4th. Five equities research analysts have rated the stock with a sell rating and four have given a hold rating to the company’s stock. Sartorius currently has an average rating of “Sell” and an average price target of €126.61 ($147.22).

Shares of FRA:SRT3 opened at €160.70 ($186.86) on Wednesday. Sartorius has a 1-year low of €71.00 ($82.56) and a 1-year high of €124.70 ($145.00).

Sartorius Company Profile

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.

Featured Story: How to interpret a stock’s beta number

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.